

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Avecho Biotechnology Limited
ABN 32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Gregory Collier
Date of last notice	27 May 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Beacon Super Fund Pty Ltd <Beacon Super Fund A/c> Gregory Collier is a Director of Beacon Super Fund Pty Ltd and a beneficiary of the fund. Barwon Biotechnology Pty Ltd Gregory Collier is a Director and Shareholder of Barwon Biotechnology Pty Ltd.
Date of change	6 May 2026 and 10 May 2026

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>Indirect <i>Beacon Super Fund Pty Ltd <Beacon Super Fund A/c></i></p> <ol style="list-style-type: none"> 4,000,000 Fully Paid Ordinary Shares (AVE) 3,000,000 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA) <p><i>Barwon Biotechnology Pty Ltd</i></p> <ol style="list-style-type: none"> 5,833,333 Fully Paid Ordinary Shares (AVE) 8,749,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA) 6,338,595 Unquoted Options exercisable at \$0.0066 each and expiring on 27 November 2028 (AVEAS)
Class	Quoted options exercisable at \$0.012 each expiring on 10 May 2026 (AVEOA); and Fully paid ordinary shares
Number acquired	800,000 fully paid ordinary shares
Number disposed	800,000 Quoted Options exercised. 10,949,000 Quoted Options expired unexercised.
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.012 per option exercised
No. of securities held after change	<p>Indirect <i>Beacon Super Fund Pty Ltd <Beacon Super Fund A/c></i></p> <ol style="list-style-type: none"> 4,800,000 Fully Paid Ordinary Shares (AVE) <p><i>Barwon Biotechnology Pty Ltd</i></p> <ol style="list-style-type: none"> 5,833,333 Fully Paid Ordinary Shares (AVE) 6,338,595 Unquoted Options exercisable at \$0.0066 each and expiring on 27 November 2028 (AVEAS)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of 800,000 ordinary shares on exercise of 800,000 Quoted Options. Expiry of 10,949,999 Quoted Options unexercised.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Avecho Biotechnology Limited
ABN	32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Matthew Patrick McNamara
Date of last notice	27 May 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	PELEHJ145 PTY LTD <M&L MCNAMARA SF A/C> Pelehj145 Pty Ltd <M&L McNamara Super Fund>Mr McNamara is a director and shareholder of the entity. He is also a beneficiary of the super fund. Pelehj145 Pty Ltd <M&L McNamara Super Fund> Mr McNamara is a director and shareholder of the entity. He is also a beneficiary of the super fund.
Date of change	10 May 2026
No. of securities held prior to change	Indirect PELEHJ145 PTY LTD <M & L MCNAMARA SFA/C> 1. 1,666,666 Fully Paid Ordinary Shares (AVE) 2. 2,499,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA) Pelehj145 Pty Ltd <M&L McNamara Super Fund> 1. 3,169,298 Unquoted Options exercisable at \$0.0066 each and expiring on 27 November 2028 (AVEAS)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Quoted options exercisable at \$0.012 each expiring on 10 May 2026 (AVEOA)
Number acquired	Nil
Number disposed	2,499,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	Indirect PELEHJ145 PTY LTD <M & L MCNAMARA SFA/C> 1. 1,666,666 Fully Paid Ordinary Shares (AVE) Pelehj145 Pty Ltd <M&L McNamara Super Fund> 1. 3,169,298 Unquoted Options exercisable at \$0.0066 each and expiring on 27 November 2028 (AVEAS)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Quoted Options on 10 May 2026

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A

+ See chapter 19 for defined terms.

Interest after change	N/A
------------------------------	-----

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Avecho Biotechnology Limited
ABN	32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ross Murdoch
Date of last notice	27 May 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	10 May 2026
No. of securities held prior to change	Direct 1. 3,333,333 Fully Paid Ordinary Shares (AVE) 2. 2,499,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA) 3. 3,169,298 Unquoted Options exercisable at \$0.0066 each and expiring on 27 November 2028 (AVEAS)
Class	Quoted options exercisable at \$0.012 each expiring on 10 May 2026 (AVEOA)
Number acquired	Nil
Number disposed	2,499,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	Direct 1. 3,333,333 Fully Paid Ordinary Shares (AVE) 2. 3,169,298 Unquoted Options exercisable at \$0.0066 each and expiring on 27 November 2028 (AVEAS)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Quoted Options on 10 May 2026

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.